Beigene's Zanubrutinib (BGB-3111) Receives the US FDA's Breakthrough Therapy Designation for Mantle Cell Lymphoma (MCL)
Shots:
- The BT designation follows the P-II trial assessing Zanubrutinib in patients with 1L mantle cell lymphoma
- Beigene’s Zanubrutinib is being evaluated globally in seven P-III trials in multiple areas including one for patients with waldenstrom macroglobulinemia (WM) with zanubrutinib vs ibrutinib and P-II for r/r follicular lymphoma in combination with Gazyva (obinutuzumab)
- Zanubrutinib (BGB-3111) is a Bruton’s tyrosine kinase (BTK) inhibitor and has also received NMPA’s (CMPA) priority review for r/r MCL and r/ r CLL/SLL in China
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
